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INTRODUCTION
Originally discovered over six decades ago,1–3 the natural product mitomy-
cin C [MMC, Fig. 1(A)] remains part of the conventional anticancer regimen
for solid tumors given its bias toward hypoxia-induced cytotoxicity.4–7
Numerous bioreductants have been implicated in MMC activation via one- or
two-electron reduction of the quinone, including nicotinamide adenine dinu-
cleotide (NADPH)/cytochrome P450 reductase, NADPH:quinone oxidoreduc-
tase (DT-diaphorase), and/or glutathione. Under oxygen-limiting conditions,
one-electron reduction predominates, producing a highly reactive quinone
methide that alkylates DNA.4,5 However, certain MMC-activating agents oper-
ate under both anaerobic and aerobic conditions [e.g., NADPH:quinone oxi-
doreductase (DT-diaphorase)] and can thereby compromise the hypoxic selec-
tivity of quinone-alkylating agents such as MMC.6 The reactivity, as well as
corresponding cytotoxic selectivity, correlates in part to the redox potential of
the quinone ring, which, in turn, can be modulated via appended functional
groups. Modifications at the C6 and C7 positions, achieved through derivatiza-
tion of naturally occurring mitomycins, provide further support for this
notion.4 Thus, understanding the structural basis for enzymes involved in
mitomycin C6 or C7, alkylation may enable the exploitation of these catalysts
toward the generation of new and improved mitomycin analogs.
Metabolic labeling studies revealed D-glucosamine and 3-amino-5-hydroxy-
benzoic acid to be the biosynthetic precursors of the mitosane skeleton, the
C-10 carbamoyl group to derive from L-arginine or L-citrulline, and the N-
and O-methyl moieties to originate from L-methionine.8–11 Based on annota-
tion of the mitomycin biosynthetic gene cluster from Streptomyces lavendulae
Agricultural Research Service Culture Collection (NRRL) 2564 [producer of
mitomycins A–C; Fig. 1(A)],12 there exist three S-adenosyl-L-methionine
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ABSTRACT
Mitomycins are quinone-containing
antibiotics, widely used as antitumor
drugs in chemotherapy. Mitomycin-
7-O-methyltransferase (MmcR), a key
tailoring enzyme involved in the
biosynthesis of mitomycin in Strepto-
myces lavendulae, catalyzes the 7-O-
methylation of both C9b- and
C9a-configured 7-hydroxymitomy-
cins. We have determined the crystal
structures of the MmcR–S-adenosyl-
homocysteine (SAH) binary complex
and MmcR–SAH–mitomycin A
(MMA) ternary complex at resolu-
tions of 1.9 and 2.3 Å, respectively.
The study revealed MmcR to adopt a
common S-adenosyl-L-methionine-
dependent O-methyltransferase fold
and the presence of a structurally
conserved active site general acid–
base pair is consistent with a proton-
assisted methyltransfer common to
most methyltransferases. Given the
importance of C7 alkylation to mod-
ulate mitomycin redox potential, this
study may also present a template to-
ward the future engineering of cata-
lysts to generate uniquely bioactive
mitomycins.
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(SAM)-dependent methyltransferase-encoding genes in
the mitomycin gene cluster.13 Of the corresponding pro-
teins, MmcR shows high sequence similarity to natural
product phenolic methyltransferases (MTases) such as
bacterial MTases involved in the biosynthesis of
calicheamicin, dynemicin, C-1027, fredericamycin, oxytet-
racycline, puromycin, and plant MTases involved in the
biosynthesis of flavonoids. Recent MmcR in vivo and in
vitro studies have revealed MmcR to catalyze the efficient
methylation of 7-demethylmitomycin A and 7-desmethyl-
mitomycin B [Fig. 1(B)] over a broader pH range in a
metal-independent manner.14 Although MmcR was dem-
onstrated to tolerate both C9a- and C9b-configurations
in vitro, the enzyme displays a strong preference for the
C9b-isomer.14 In an effort to further our understanding
of the mechanism of MmcR catalysis and the key struc-
tural elements for SAM recognition and activation,
herein, we report the crystal structures of the MmcR–S-
adenosylhomocysteine (SAH) binary complex and
MmcR–SAH–mitomycin A (MMA) ternary complex at
resolutions of 1.9 and 2.3 Å, respectively. This work
reveals MmcR to crystallize as a dimer and to adopt a
fairly typical MTase structural fold. Given the ability of
structurally homologous DNA- and natural product-
MTases to use non-natural cofactor analogs of SAM to
achieve differential alkylation,15–22 this study supports
the notion that MmcR (in conjunction with SAM surro-
gates) may also present an opportunity to further modu-
late the redox potential of mitomycin.
MATERIALS AND METHODS
Mitomycin A synthesis
Mitomycin C (109 mg, 0.326 mmol) was suspended in
an aqueous solution of NaOH (0.05M, 8 mL) under Ar at
room temperature and was excluded from light. After stir-
ring for 16 h, the sodium mitosane salt (Rf 5 0.08, 10%
MeOH in CH2Cl2) was cooled to 08C and acidified to a pH
of 3.9 with 0.1M H2SO4. The aqueous solution was
extracted with EtOAc (4 3 10 mL) and then dried with
Na2SO4. Evaporation of the solvent yielded the hydroxymi-
tosane as a purple solid (95 mg). Methylation was per-
formed by first dissolving the solid in tetrahydrofuran
(THF) (20 mL) and cooling to 08C, and then slowly adding
an ethereal solution of diazomethane (20 mL; prepared by
adding 250 mg of N-methyl-N0-nitro-N-nitrosoguanidine
to 20 mL of 40% aqueous KOH and 20 mL Et2O). The reac-
tion proceeded for 10 min at 08C and was quenched with
HOAc (250 lL). After removing the solvent, the residue was
purified by column chromatography (SiO2, 5% MeOH in
CH2Cl2) providing mitomycin A as an amorphous solid (43
mg, 43%, TLC, Rf 5 0.51, 10% MeOH in CH2Cl2).
1H
NMR (acetone-d6, 500 MHz) d 5.94 (br s, 2H), 4.72 (dd, J
5 10.6, 4.4 Hz, 1H), 4.30 (t, J5 10.6 Hz, 1H), 4.02 (s, 3H),
3.93 (d, J 5 12.5 Hz, 1H), 3.51 (dd, J 5 11.0, 4.4 Hz, 1H),
3.42 (d, J5 12.1 Hz, 1H), 3.21 (s, 3H), 2.90 (br s, 1H), 2.84
(br s, 1H), 1.79 (s, 3H); 13C NMR (acetone-d6, 125 MHz) d
184.3, 179.7, 159.3, 158.4, 153.5, 125.3, 116.0, 108.3, 63.5,
62.5, 51.8, 50.8, 45.9, 38.2, 34.3, 9.2; HRMS (ESI) m/z
C16H19N3NaO6 ([M1Na]
1) 372.1171, calculated 372.1166.
Protein expression and purification
Recombinant N-His6-MmcR (herein, referred to sim-
ply as MmcR) was produced in Escherichia coli and affin-
ity purified as previously described.14 The purified
enzyme in 20 mM Tris, pH 8, 50 mM NaCl was subse-
quently concentrated to 20 mg/mL, drop frozen in liquid
nitrogen, and stored at 2808C. Protein concentrations
were determined by Bradford assay (Bio-Rad, Hercules,
CA) using bovine serum albumin (BSA) as a standard.
For the production of selenomethionine (SeMet)-labeled
protein, the E. coli methionine auxotroph strain B834
(DE3) was transformed with plasmid N-His6-mmcR14
and the production of the desired (SeMet)-labeled
recombinant protein accomplished using autoinduction
media.23
Protein crystallization
Crystals of MmcR with SAH were grown by vapor dif-
fusion in hanging drops containing a 1:1 mixture of 1 ll
protein and 1 ll crystallization buffer [10% (w/v) poly-
ethylene glycol 4000, 15% 2-methyl-2,4-pentadiol
(MPD), 100 mM CaCl2, and 100 mM 2-(N-morpholi-
no)ethanesulfonic acid (MES) (pH 6.0) at 48C]. Crystals
of MmcR in complex with MMA were obtained by soak-
ing the MmcR–SAH crystals in the crystallization solu-
tion with 5 mM MMA for 8 h. Diffraction data were col-
lected from a single crystal that was soaked in crystalliza-
tion solution containing 25% ethylene glycol, mounted
Figure 1
(A) Naturally occurring mitomycins. (B) The reaction catalyzed by
MmcR.
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in a cryoloop and flash frozen in a stream of liquid
nitrogen.
MmcR structure determination
All diffraction data for SeMet-labeled MmcR–SAH
complexes were collected at the General Medicine and
Cancer Institute Collaborative Access Team (GM/CA-CAT)
23-ID-D beamline at the Advanced Photon Source of
Argonne National Laboratory. Each of the 180 diffraction
images for the SeMet-labeled crystals was collected at a
crystal-to-detector distance of 270 mm, exposed for 5 s, in
a single pass with 18 oscillation per frame. Data sets for the
MmcR–SAH complex were collected at two wavelengths:
0.97945 and 0.96421 Å. The diffraction images were
indexed, integrated, and scaled using HKL2000.24 Diffrac-
tion data for SeMet-labeled MmcR–SAH–MMA complexes
were collected at the Life Science Collaborative Access Team
(LS-CAT) 21-ID-F beamline at the Advanced Photon
Source of Argonne National Laboratory. Each of the 120 -
diffraction images for the SeMet-labeled crystals was col-
lected at the crystal-to-detector distance of 225 mm,
exposed for 4 s, in a single pass with 18 oscillation per
frame and at 0.97872 Å wavelength. The diffraction images
were indexed, integrated, and scaled using HKL2000.
Both complexes crystallized in space group P212121 with
four molecules per asymmetric unit. Unit cell dimensions
for MmcR–SAH were a 5 88.3 Å, b 5 98.9 Å, and
c 5 171.1 Å and for MmcR–SAH–MMA were a 5 87.8 Å,
b 5 98.8 Å, and c 5 171.0 Å.
Phases for the MmcR–SAH complex were determined
using the multiple wavelength anomalous dispersion
method on SeMet-substituted protein. Initial heavy atom
sites were found using the programs PHENIX.HySS25
and SHELXD.26,27 PHENIX.EMMA identified 16 con-
sensus sites. The structure was automatically phased, and
density modification was performed using auto-
SHARP.28 Using the initial phase information, a high-re-
solution model of MmcR–SAH was built in ARP/
wARP.29 Using the MmcR–SAH structure as a search
model, the MmcR–SAH–MMA structure was obtained by
molecular replacement using MOLREP.30 The structure
was completed via multiple manual interactions in
COOT31 followed by refinement in REFMAC532 and
PHENIX.Refine.33 The quality of all models was assessed
using the program MOLPROBITY34 and PROCHECK.35
The final model of MmcR–SAH contained residues 11–
349 in each of the 4 monomers, 871 water molecules, 4
molecules of SAH, and MPD. The MmcR–SAH–MMA
model contained residues 11–349, 329 water molecules,
and 4 molecules of SAH and MMA. Topology and
parameter files for SAH and MPD were obtained from
the REFMAC library. Topology and parameter files for
MMA were obtained by modifying the MMC structure
with SKETCHER.36 All figures are generated using
molecular graphics program PyMOL. The binary and
ternary complexes have been deposited under accession
numbers 3GWZ and 3GXO, respectively.
RESULTS AND DISCUSSION
Recombinant MmcR, a 38-kDa protein consisting of
349 amino acids, was expressed in E. coli as N-terminal
polyhistidine-tagged protein and purified by Ni21 affinity
chromatography. In the MmcR–SAH and MmcR–SAH–
MMA binary and ternary complexes, the first 30 residues
of chain A–D (20 residues of which comprised the N-ter-
minal His-tag in each case) were not modeled due to
insufficient electron density. The electron density for the
rest of the polypeptide chain and the bound ligands is
well defined [Fig. 2(A,B)]. The final structure was refined
to an Rcryst and Rfree of 17.4% and 21.0% for MmcR–
SAH and 20.2% and 25.5% for MmcR–SAH–MMA com-
plex, respectively (Table I).
Overview of the structure
Each subunit of MmcR exhibited a C-terminal catalytic
domain and N-terminal dimerization domain. The
C-terminal domain contains the conserved DXGXGXG
fingerprint needed for cofactor binding. It is folded into a
Rossmann fold, comprising a central parallel b-sheet (b1–
b7), where all except b7 are parallel to each other and
surrounded by seven alternating a-helices (a10–a16)
[Fig. 3(A)]. The sequence of secondary structural ele-
ments in this core SAM-binding domain is composed of
a10, b1, a11, b2, a12, b3, b4, g13, a14, b5, a15, a16,
b6, and b7. The N-terminal domain involved in dimeri-
zation and for substrate binding contains all a-helical sec-
ondary structural elements. The secondary elements
mainly engaged in dimer formation include the helices
a1, a4, a6, a7, and a15 [Fig. 3(B)]. The interaction area
of dimer interface is 3146 Å2 [Fig. 3(B)], mostly domi-
nated by hydrophobic interactions along with 29 hydro-
gen bonds and 17 salt bridges. Analysis of crystal packing
does not support the formation of a tetramer, as the
interaction in the crystal lattice is rather weak. The largest
interaction area with an adjacent molecule is only 467 Å2,
indicative of crystal contacts rather than a protein–pro-
tein interface. This is consistent with biochemical analysis
by native sodium dodecyl sulfate/polyacrylamide gel
electrophoresis (determined MW 73.2 kDa; calculated
MW for the dimer, 75.2 kDa; data not shown). The
MmcR-bound product (MMA) is situated at the interface
of N- and C-terminal domains [Fig. 3(A)], and residues
from both of these domains are involved in product
binding. The fold of MmcR very much resembles
previously reported O-MTases such as carminomycin
4-O-methyltransferase (DnrK),37 neocarzinostatin
O-methyltransferase (NcsB1),38 chalcone O-methyltrans-
ferase (ChOMT),39 isoflavone O-methyltransferase
Structural Characterization of MmcR
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Table I
Crystal Parameters, X-ray Data Collection, Phasing, and Refinement Statistics
MmcR–SAH MmcR–SAH–MMA
Crystal parameters Peak HRem
Space group P212121 P212121 P212121
Unit-cell parameters (, 8) a 5 88.3, b 5 98.9, c 5 171.1 a 5 88.5, b 5 99.0, c 5 171.4 a 5 87.8, b 5 98.8, c 5 171.0
Data collection statistics
Wavelength () 0.97945 0.96421 0.97872
Energy (eV) 12658.6 12858.6 12,668
Resolution range () 50.00–1.91 (1.98–1.91) 100.00–2.00 (2.07–2.00) 50.00–2.30 (2.38–2.30)
No. of reflections (measured/unique)a 220,672/115,235 194,218/101,748 708,974/59,548
Completeness (%) 98.6 (87.9) 98.8 (92.2) 88.8 (70.7)
Rmerge
b 0.113 (0.570) 0.128 (0.903) 0.092 (0.315)
Redundancy 13.6 (9.2) 13.3 (9.3) 3.9 (3.3)
Mean I/sigma(I) 11.5 (2.4) 11.3 (3.9)
Phasing statistics
Mean FOM (centric/acentric) 0.090/0.322
Phasing power (isomorphous/anomalous) 0.0/0.98
Cullis R-factor (isomorphous/anomalous) 0.0/0.84
Refinement and model statistics
Resolution range 19.65–1.91 (1.93–1.91) 43.92–2.30 (2.38–2.30)d
No. of reflections (work/test) 114,971/5763 59,450/3003
Rcryst
e 0.174 (0.253) 0.202 (0.235)
Rfree
f 0.210 (0.333) 0.255 (0.298)
RMSD bonds () 0.006 0.007
RMSD angles (8) 1.000 1.102
ESU from Rfree ()
g 0.23 0.19
B-factor—overall/waters (2)h 23.4/40.4 36.5/40.9
No. of protein molecules/all atoms 4/11428 4/10866
No. of waters 871 329
Ramachandran plot by MOLPROBITY (%)
Favored regions 98.7 97.6
Additional allowed regions 1.2 2.4
Outliers 0.1 0.0
PBD code 3GWZ 3GXO
aValues in parentheses are for the highest resolution shell.
bRmerge 5 ShSi|Ii(h) 2 <I(h)>|/ShSiIi(h), where Ii(h) is the intensity of an individual measurement of the reflection and <I(h)> is the mean intensity of the reflection.
cResolution range for phasing in SHARP was (26.66–3.2) Å.
dResolution range for refinement was cut (38.76–1.90) Å due to low completeness and signal in the remaining resolution shells.
eRcryst 5 Sh||Fobs| 2 |Fcalc||/Sh|Fobs|, where Fobs and Fcalc are the observed and calculated structure–factor amplitudes, respectively.
fRfree was calculated as Rcryst using 5.0% of the randomly selected unique reflections that were omitted from structure refinement.
gEstimated standard uncertainty based on Rfree.
hB-factors from the model refined without TLS.
Figure 2
Simulated annealing omit Fo 2 Fc electron density maps contored at 3r. (A) Bound SAH and (B) bound MMA in MmcR–SAH–MMA ternary
complex.
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(IOMT),39 calicheamicin O-methyltransferase (CalO1),40
and caffeic acid/5-hydroxyferulic acid 3/5 O-methyltrans-
ferase (COMT).41
The SAM/SAH-binding site
In both determined structures, the cofactor product
SAH is well defined by electron density [Fig. 2(A)].
MmcR bears a signature motif (DXGXGXG) containing
highly conserved residues for the recognition of SAM/
SAH and, like all SAM-dependent MTases, contains
conserved active site residues to provide a network of
hydrogen-bonding interactions [Fig. 3(C)] with the do-
nor and acceptor of the methyl group (see Fig. 4 for
sequence alignment with representative homologs). The
carboxylate group of SAH forms an electrostatic inter-
Figure 3
(A) Overview of the secondary structural elements in the MmcR–SAH–MMA ternary complex (helices are colored blue, strands are colored
magenta, ligands SAH and MMA are colored yellow, letters N and C correspond to the N-terminus and C-terminus of the MmcR protein,
respectively). (B) Ribbon representation of MmcR–SAH–MMA ternary complex quaternary structure, showing dimer interfaces. In this
representation, the two monomers are colored red and blue and ligands SAH and MMA are colored cyan and yellow, respectively. (C) Stereoview of
interaction of SAH and MMA in MmcR–SAH–MMA complex. The stick model of SAH and MMA are depicted in magenta and yellow, respectively.
The interacting MmcR residues are labeled and illustrated in blue, green, and cyan for hydrophobic, charged, and neutral residues, respectively.
Polar interactions are depicted by orange dashed lines.
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action with side chains of Ser167 and Lys255. The ter-
minal amino group participates in a hydrogen bonding
network not only in direct interactions with the back-
bone oxygen of Gly190 and Lys255 but also indirectly
with the backbone nitrogen of Lys255, the backbone
oxygen of Ile189, and the side chain oxygen of Asp188
via water molecules. The adenine ring forms stacking
interactions with the side chains of Trp261 and
Phe241, and Asp240 forms a hydrogen bond to the N6
amino group. The ribose moiety is anchored to MmcR
through hydrogen bonds of the O2* and O3* hydroxyl
groups to the side chains of Glu213 and Arg214.
Lys255 interacts with both the carboxyl group and the
amino group of SAM/SAH, and the latter also forms a
hydrogen bond to the main chain carbonyl oxygen of
Gly190. The SAH sulfur atom makes hydrophobic
interactions with side chains of Phe159 and Met163.
Most of these interactions are globally conserved
among the MTase family.
The substrate-binding site
The product, MMA, fits well into the electron density
[Fig. 2(B)] observed at the interface between the N-terminal
and C-terminal domain, close to the cofactor binding
site [Fig. 3(A)]. The binding of MMA to MmcR is domi-
nated by hydrophobic and van der Waals interactions
involving residues Phe113, Phe145, Trp146, Phe159,
Ala162, Met163, Val166, Val301, Leu304, Leu305, Leu308,
Val309, and Val341 [Fig. 3(C)]. Apart from the van der
Waals interactions to the enzyme, MMA is anchored to
its binding site also by a few hydrogen bonding interac-
tions. Specifically, MMA N2 forms a hydrogen bond to
the main chain oxygen of Ala162, whereas MMA atoms
O7 and O8 interact with the side chain of His259.
Figure 4
Alignment of selected structural homologs of MmcR identified by DALI search: calicheamicin-O-methyltransferase CalO1 (PDB: 3LST);
neocarzinostatin-O-methyltransferase NcsB1 (PDB: 3I5U); isoflavone methyltransferase IOMT (PDB: 1FP2); carminomycin-4-O-methyltransferase
Dnrk (PDB: 1TW3); and aclacinomycin hydroxylase RdmB (PDB: 1QZZ). The alignment was generated by the Multalin-4.1 web-server using
default parameters. Residues with sequence consensus above 90% and 50% are colored red and blue, respectively. Yellow boxes highlight the
putative catalytic residues.
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Structural comparison of the MmcR–SAH
complex and MmcR–SAH–MMA ternary
complex
The four subunits of complexes of MmcR–SAH and
MmcR–SAH–MMA structures align with a r.m.s. devia-
tion of 0.31 for 8785 structurally corresponding atoms.
The dimers of MmcR–SAH and the MmcR–SAH–MMA
complex align with r.m.s. deviation of 0.28 for 4237
structurally corresponding atoms. These low values indi-
cate no large-scale changes in tertiary and/or quaternary
structure to occur on substrate binding. The occupancy
of the MMA-binding site by MPD in MmcR–SAH crys-
tal form (i.e., representing a ‘‘substrate-bound’’ form)
may partially explain the high degree of similarity
between the MmcR–SAH and the MmcR–SAH–MMA
structures. The only notable structural variation occurs
within the solvent-exposed loops surrounding the prod-
uct MMA (residues 100–106, 289–294, and 335–342),
suggesting subtle loop movements in the context of
ligand binding.
Structural homology
A DALI search for MmcR structural homologs in the
Protein Data Bank (PDB) database returned several hits.
Among those, which displayed the highest Z-score were
carminomycin 4-O-methyltransferase (DnrK),37 neocar-
zinostatin O-methyltransferase (NcsB1),38 aclacinomycin
hydroxylase (RdmB),42 isoflavone methyltransferase
(IOMT),39 and calicheamicin O-methyltransferase
(CalO1),40 with Z-scores 37, 36, 34, 33, and 32 respec-
tively. They share 25–35% overall sequence identity
with MmcR. Highest sequence conservation is found
among residues associated with SAM-binding—specifi-
cally, the loop that interacts with the homocysteine and
ribosyl moieties of the SAH situated between b1 and a11
(which contains the glycine-rich consensus sequence
DXGXGXG) and an acidic residue in loop between b3
and b4 (Asp240 in MmcR), which interacts with the exo-
cyclic N6 and ring nitrogen N1 of adenine ring of the
cofactor. MmcR gives a r.m.s. deviation of 1.7, 1.9, 2.1,
3.2, and 3.7 Å over 330 Ca, 321 Ca, 323 Ca, 330 Ca, and
345 Ca atoms with DnrK, NcsB1, RdmB IOMT, and
CalO1, respectively, and like these three MTases, MmcR
is dimeric and also shares high structural similarity
across the dimerization domain. Similar to most methyl-
transferases,39 His259 and Glu313 are implicated as gen-
eral acid/base pair [Figs. 3(C) and 4] for MmcR catalysis.
Specifically, His259 is within range (3.3 Å) [Fig. 3(C)] to
deprotonate the hydroxyl group of 7-desmethyl MMA,
whereas Glu313 is within the hydrogen bonding distance
(3.0 Å) [Fig. 3(C)] of His259 to potentially constrain and
orient the catalytic base. Consistent with a putative acid/
base-mechanism for MmcR, divalent metals do not influ-
ence MmcR activity.14
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